Program
Dextromethorphan
Also written as “dextromethorphan”, “Drug Cocktail” and “AVP-923-20”.
Its studies are mostly in Neoplasm Metastasis · Multiple Sclerosis · Cough · Nasal Obstruction · Diabetes Mellitus, Type 2, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Otsuka | 40 open or running | phase 4since Feb 25, 2013 | Dec 13, 2007 | none ahead |
| Pfizer | 20 open or running | phase 4since Dec 7, 2010 | Dec 7, 2010 | none ahead |
| Johnson & Johnson | 10 open or running | phase 3since Jan 15, 2018 | Jan 15, 2018 | none ahead |
| Profil Institut für Stoffwechselforschung | 10 open or running | phase 2since Aug 28, 2013 | Aug 28, 2013 | none ahead |
Also a collaborator on its studies: parexel, Boehringer Ingelheim, Novartis, perrigo-company, Procter and Gamble and Reckitt.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 13, 2007First study: phase 3 study in Amyotrophic Lateral SclerosisNew to OtsukaOtsuka · NCT00573443 · 326 enrolled · United States, Argentina, Brazil
- Dec 7, 2010Pfizer's first study: phase 4 study in Common ColdNew to PfizerPfizer · NCT01257542 · 140 enrolled · United States
- Mar 23, 2011Phase 2 study in Multiple SclerosisOtsuka · NCT01324232 · 209 enrolled · United States, Argentina, Czechia and more
- Feb 25, 2013Phase 4 study in StrokeOtsuka · NCT01799941 · 367 enrolled · United States
- Aug 28, 2013Profil Institut für Stoffwechselforschung's first study: phase 2 study in Diabetes Mellitus, Type 2New to Profil Institut für StoffwechselforschungProfil Institut für Stoffwechselforschung · NCT01936025 · 34 enrolled · Germany
- Jul 8, 2015Phase 4 study in Pseudobulbar Affect (Involuntary Laughing and/or Crying)Otsuka · NCT02496039 · 5 enrolled · United States
- Jan 7, 2016Phase 4 study in CoughPfizer · NCT02651116 · 131 enrolled · United States
- Jan 15, 2018Johnson & Johnson's first study: phase 3 study in Nasal ObstructionNew to Johnson & JohnsonJohnson & Johnson · NCT03439436 · 140 enrolled · Russian Federation
TargetBeta
“Sigma opioid receptor agonist; Sigma opioid receptor agonist; Glutamate [NMDA] receptor subunit epsilon 1 antagonist; Glutamate [NMDA] receptor subunit epsilon 1 antagonist”ChEMBL 37, by rule
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT03439436Nasal Obstruction · Russian Federation | 3 | Completed | Johnson & Johnson | May 2, 2018 | 140 |
| NCT02651116Cough · United States | 4 | Terminated | Pfizer | Mar 19, 2020 | 131 |
| NCT02496039Pseudobulbar Affect (Involuntary Laughing and/or Crying) · United States | 4 | Terminated | Otsuka | May 2016 | 5 |
| NCT01936025Diabetes Mellitus, Type 2 · Germany | 2 | Completed | Profil Institut für Stoffwechselforschung | Apr 2014 | 34 |
| NCT01799941Stroke · United States | 4 | Completed | Otsuka | May 2015 | 367 |
| NCT01324232Multiple Sclerosis · United States, Argentina, Czechia and more | 2 | Completed | Otsuka | Sep 26, 2013 | 209 |
| NCT01257542Common Cold · United States | 4 | Terminated | Pfizer | Mar 2011 | 140 |
| NCT00573443Amyotrophic Lateral Sclerosis · United States, Argentina, Brazil | 3 | Completed | Otsuka | Jun 2009 | 326 |
How it is read
Names in the registry
- “Dextromethorphan”, 6 entries
- “dextromethorphan”, 1 entry
- “Drug Cocktail”, 1 entry
- “AVP-923-20”, 1 entry
- “Dextromethorphan Hydrobromide”, 1 entry
Conditions, from the studies’ own filings
- Neoplasm Metastasis, 1 study
- Multiple Sclerosis, 1 study
- Cough, 1 study
- Nasal Obstruction, 1 study
- Diabetes Mellitus, Type 2, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.